Latest News on LGND

Financial News Based On Company


Advertisement
Advertisement

One holder reports 914,350 Ligand Pharmaceuticals (LGND) shares, all with shared voting rights.

https://www.stocktitan.net/sec-filings/LGND/schedule-13g-a-ligand-pharmaceuticals-inc-amended-passive-investment--2a3c5f8710d1.html
Janus Henderson Group Ltd. has filed an amended Schedule 13G/A report indicating beneficial ownership of 914,350 common shares of Ligand Pharmaceuticals Incorporated (LGND), representing 4.6% of the class. The firm reports shared voting and dispositive power over all these shares. This filing is a passive investment disclosure and states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

A director proposes selling 2,000 Ligand (LGND) shares around November 12, 2026.

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-6255a1f4bda8.html
Ligand Pharmaceuticals Inc. director Martine Zimmermann has filed a notice proposing to sell 2,000 common shares of LGND, valued at approximately $636,336.20, around November 12, 2026. The filing also indicates that Zimmermann previously sold 1,200 common shares on September 10, 2026, for gross proceeds of $342,000.00. This Form 144 SEC filing provides details on the proposed sale and Zimmermann's prior transactions.

A director proposes selling 500 Ligand (LGND) shares worth $159K.

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-2d13b292aef0.html
John Kozarich, a director at Ligand Pharmaceuticals Inc. (LGND), has proposed selling 500 common shares valued at $158,659.25. The approximate sale date is November 11, 2026, through UBS Financial Services, Inc. This proposed sale is being conducted under Rule 10b5-1, with the plan adoption date listed as August 12, 2026.

Form 144 LIGAND PHARMACEUTICALS INC For: 11 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-ligand-pharmaceuticals-inc-for-11-november-93CH-4975085
This article announces the filing of Form 144 for Ligand Pharmaceuticals Inc. on November 11. It's a brief news item from Investing.com, likely indicating an insider's intent to sell restricted stock. The content provides the company's stock symbol (LGND) and a slight price increase.

No one person tops 5% economic ownership in Invesco’s reported Ligand (LGND) stake.

https://www.stocktitan.net/sec-filings/LGND/schedule-13g-a-ligand-pharmaceuticals-inc-amended-passive-investment--bdc10663e80c.html
Invesco Ltd., acting as a parent holding company, has reported beneficial ownership of 1,520,911 common shares, or 7.6% of Ligand Pharmaceuticals Inc. (LGND), as of September 30, 2026. This disclosure indicates Invesco holds sole voting power over 1,497,232 shares and sole dispositive power over all 1,520,911 shares, with no individual having greater than 5% economic ownership within this reported stake. The shares are held by Invesco clients, and the filing is classified as a SCHEDULE 13G/A.
Advertisement

A director proposes selling 3,000 shares worth $960K at Ligand Pharmaceuticals (LGND).

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-e5220dd9fbc3.html
Ligand Pharmaceuticals Inc. director Jason Aryeh has filed a notice of proposed sale for 3,000 shares of Class B common stock, valued at approximately $960,084.19, with an approximate sale date of November 10, 2026. The filing also details four earlier sales by Aryeh between October 30 and November 4, 2026, with reported gross proceeds for each transaction. This information was made available through an SEC Form 144 filing.

Form 144 LIGAND PHARMACEUTICALS INC For: 5 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-ligand-pharmaceuticals-inc-for-5-november-93CH-4933227
This article from Investing.com announces the filing of Form 144 for Ligand Pharmaceuticals Inc. on November 5. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the announcement.

Form 144 LIGAND PHARMACEUTICALS INC For: 5 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-ligand-pharmaceuticals-inc-for-5-november-93CH-4959645
This article reports on a Form 144 filing for Ligand Pharmaceuticals Inc. on November 5. Form 144 is a notice of the intent to sell restricted stock, indicating potential insider trading activity. The brief announcement provides the company name and filing date, along with its stock symbol LGND.

Form 144 LIGAND PHARMACEUTICALS INC For: 3 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-ligand-pharmaceuticals-inc-for-3-november-93CH-2776857
This article reports on a Form 144 filing for Ligand Pharmaceuticals Inc. on November 3, 2026. The filing is a standard regulatory disclosure related to proposed sales of restricted and control securities. The article provides minimal detail beyond the announcement of the filing itself.

Form 144 LIGAND PHARMACEUTICALS INC For: 3 November By Investing.com

https://za.investing.com/news/stock-market-news/form-144-ligand-pharmaceuticals-inc-for-3-november-93CH-4544825
This article from Investing.com announces the filing of Form 144 for Ligand Pharmaceuticals Inc. on November 3, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider trading activity or significant share transactions. The brief report highlights the date of the filing and mentions Ligand Pharmaceuticals Inc. by its stock symbol LGND.
Advertisement

Form 144 LIGAND PHARMACEUTICALS INC For: 3 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-ligand-pharmaceuticals-inc-for-3-november-93CH-4924194
This article announces the filing of Form 144 for LIGAND PHARMACEUTICALS INC (LGND) on November 3, 2026. The filing is a standard SEC disclosure related to proposed sales of restricted and control securities. The article provides the title and a brief mention of the company's stock performance.

A director proposes selling 1,209 Ligand Pharmaceuticals (LGND) shares around October 30, 2026.

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-9bc6fadcbf42.html
Ligand Pharmaceuticals Inc. director Jason M. Aryeh has proposed selling 1,209 common shares of the company, valued at approximately $385,185.47, with an anticipated sale date of October 30, 2026. These shares are identified as restricted stock, which he acquired from Ligand Pharmaceuticals Inc. on June 5, 2026. The sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services.

Director Jason M. Aryeh plans a $64,738 share sale at Ligand Pharmaceuticals (LGND).

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-8fa1608f59a4.html
Ligand Pharmaceuticals Inc. (LGND) director Jason M. Aryeh has filed a Form 144 to sell 202 common shares, valued at $64,738.00, through Charles Schwab & Co., Inc. The shares were acquired via an open-market purchase on March 13, 2019, and the approximate sale date is listed as October 30, 2026. This planned sale represents a small fraction of the company's 19,935,609 outstanding shares.

Ligand: Q3 Earnings Snapshot

https://www.kare11.com/article/syndication/associatedpress/ligand-q3-earnings-snapshot/616-a488abdf-972c-41d7-af0b-c7f0feb4e04a
Ligand Pharmaceuticals Inc. (LGND) reported a third-quarter loss of $28.5 million, or $1.43 per share. However, adjusted earnings of $2.67 per share surpassed Wall Street expectations. The drugmaker also exceeded revenue forecasts, posting $78.7 million for the period, and provided full-year earnings and revenue guidance.

Oppenheimer's top 50 small- and mid-cap Buy list

https://www.tradingview.com/news/seekingalpha:071edf3f0094b:0-oppenheimer-s-top-50-small-and-mid-cap-buy-list/
Oppenheimer technical analyst Ari Wald has updated the firm's list of 50 top small- and mid-cap Buy ideas, covering a wide range of sectors. New additions to the list include Permian Resources, James Hardie Industries, SS&C Technologies, Watts Water Technologies, SharkNinja, Nurix Therapeutics, Rubrik, Bentley Systems, and Dropbox. The list is part of Oppenheimer’s market- and sector-neutral SMID-cap 50/50 strategy, which pairs 50 Buy ideas with 50 Sells and includes Momentum Overlay scores based on risk-adjusted returns.
Advertisement

LGND Stock Price, Quote & News

https://www.syfe.com/stocks/us/lgnd
This article provides an overview of Ligand Pharmaceuticals Incorporated (LGND) stock, including its current trading price, market capitalization, and key financial statistics. It also highlights recent company news such as analyst ratings, investments, acquisitions, and insider trading activity. The article also answers frequently asked questions about LGND stock and lists related biopharmaceutical stocks.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) Earnings, Actual EPS, EPS Estimates & Results

https://stocktwits.com/symbol/LGND/earnings
This article provides an overview of Ligand Pharmaceuticals, Inc. (LGND) earnings, including estimated and historical EPS and revenue data. The company's upcoming Q3 '26 earnings report is scheduled for November 5th, with an estimated EPS of $2.31 and estimated revenue of $77.95 million. Recent quarters show a mix of beating and missing EPS estimates.

Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation (LGND:NASDAQ)

https://seekingalpha.com/news/4647278-ligand-pharma-a-new-outperform-at-barclays-on-biopharma-royalty-aggregation
Barclays initiated coverage on Ligand Pharmaceuticals (LGND) with an Outperform rating, setting a price target of $345. The investment bank believes Ligand's transition to biopharma royalty aggregation could drive long-term revenue growth exceeding 20%. This positive outlook is based on the company's new business model focused on aggregating royalties from various biopharmaceutical assets.

A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-a409098a3847.html
Ligand Pharmaceuticals (NASDAQ: LGND) director Martine Zimmermann has filed a Rule 144 notice to sell 1,200 common shares with an aggregate market value of $342,000. The shares, originating from restricted stock grants in 2024 and 2025, are expected to be sold through Morgan Stanley Smith Barney LLC on or about September 10, 2026. This sale represents a small fraction of the 19,935,609 outstanding shares.

Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs

https://www.valueresearchonline.com/stocks/291482/ligand-pharmaceuticals-incorporated-lgnd/shareholding/
This article provides a detailed shareholding pattern for Ligand Pharmaceuticals Incorporated (LGND), including institutional holdings over several quarters and recent insider trading activities. It shows that institutional investors like Vanguard Group Inc., Macquarie Group Ltd, and BlackRock Inc. hold significant stakes, with varying changes in their holdings over time. The insider trading section lists recent "Sell" transactions by company individuals.
Advertisement

Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock

https://www.moomoo.com/news/post/74735786/ligand-pharmaceuticals-lgndus-officer-sells-us-9-24-million-in
An officer at Ligand Pharmaceuticals (LGND.US) recently sold a significant amount of common stock, totaling US$9.24 million. This transaction indicates a notable insider trading activity for the company.

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run

https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-stock-trades-111117444.html
Ligand Pharmaceuticals (LGND) stock has seen a significant 337.4% return over the past five years, yet its valuation presents a mixed picture. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 32.4% with an intrinsic value of $427 per share, while its P/E ratio of 29.2x indicates it is overvalued compared to the industry average. This discrepancy highlights differing views on the company's future cash flow stability and growth prospects, especially after the expansion of its royalty portfolio.

Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals

https://www.stocktitan.net/sec-filings/LGND/schedule-13g-ligand-pharmaceuticals-inc-passive-investment-disclosure-5ad6068dc36d.html
Invesco Ltd. has reported a 6.1% beneficial ownership stake in Ligand Pharmaceuticals Inc., according to a recent SCHEDULE 13G SEC filing. This represents 1,218,846 shares of Ligand's common stock, with Invesco exercising sole voting power over 1,199,033 shares and sole dispositive power over all 1,218,846 shares. The shares are held by Invesco's advisory clients, none of whom hold more than 5% economic ownership individually.

Ligand Pharmaceuticals Q2 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:97d4ce1fc094b:0-ligand-pharmaceuticals-q2-earnings-call-highlights/
Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings, and highlighted the strategic acquisition of XOMA Royalty. The company raised its full-year adjusted EPS guidance and outlined significant deployable capital for future business development. Ligand also detailed its expanded commercial portfolio and pipeline catalysts, including several key programs and upcoming trial readouts.

Janus Henderson Group PLC Raises Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

https://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-raises-stock-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-07-31/
Janus Henderson Group PLC increased its stake in Ligand Pharmaceuticals Incorporated by 1.5% in the first quarter, now owning over 1 million shares valued at approximately $201.6 million. Institutional investors hold a significant portion of the company's stock, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $319. Despite insider selling and a recent earnings miss, Ligand's shares are trading near their 12-month high.
Advertisement

LGND|Ligand Pharmaceuticals Inc|Price:289.855|Chg%:+2.315

https://www.tradingkey.com/markets/stocks/lgnd/company
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that focuses on enabling scientific advancement through financing and licensing its proprietary technologies, such as Captisol and NITRICIL, to support the clinical development of medicines. The company has a market capitalization of $6.26 billion and a P/E TTM of 40.72. Its Contract Revenue-Other business was the largest revenue source in Q1 2026, generating $66.87 million.

July 2026's Stocks That May Be Priced Below Estimated Value

https://simplywall.st/stocks/us/tech/nyse-bdc/belden/news/july-2026s-stocks-that-may-be-priced-below-estimated-value
This article identifies US stocks that may be undervalued based on cash flow analysis, despite a recent market decline. It highlights three specific companies—Ligand Pharmaceuticals (LGND), Legence (LGN), and Belden (BDC)—providing an overview of their operations, estimated discounts to fair value, and growth prospects. The analysis suggests these companies could offer opportunities for investors looking to capitalize on market inefficiencies.

Bessemer Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated $LGND

https://www.marketbeat.com/instant-alerts/filing-bessemer-group-inc-increases-position-in-ligand-pharmaceuticals-incorporated-lgnd-2026-07-19/
Bessemer Group Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 358.8% in Q1, now owning 107,859 shares worth $21.5 million. Despite missing recent earnings and revenue estimates, Wall Street maintains a "Moderate Buy" consensus rating with an average price target of $304.00, with several analysts raising their price targets, including Bank of America to $388.00.

ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks

https://www.tradingview.com/symbols/MUN-LGDN/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ligand Pharmaceuticals Incorporated (LGDN). It provides a detailed table including each ETF's market value, weight of LGDN in the fund, issuer, management style, focus (e.g., small cap, health care), expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds with exposure to Ligand Pharmaceuticals and assess their characteristics.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP

https://www.finansavisen.no/borsmeldinger/2026/06/10/b7c3ac32-2bdd-5ad4-94cb-95064662c4f1/shareholder-alert-the-m-and-a-class-action-firm-continues-to-investigate-the-merger-tmhc-czr-xoma-and-ramp
Monteverde & Associates PC, an M&A class action firm, is investigating several mergers impacting shareholders of Taylor Morrison Home Corp. (TMHC), Caesars Entertainment, Inc. (CZR), XOMA Royalty Corporation (XOMA), and LiveRamp Holdings, Inc. (RAMP). The firm is encouraging shareholders of these companies to seek information regarding the proposed sale terms and their rights. They emphasize their track record of recovering funds for shareholders through litigation.
Advertisement

Ligand Raises $700M Via 0% Convertible Notes, Adds Note Hedges and $524.34 Strike Warrants

https://www.tradingview.com/news/tradingview:f677881e7446a:0-ligand-raises-700m-via-0-convertible-notes-adds-note-hedges-and-524-34-strike-warrants/
Ligand Pharmaceuticals has successfully completed a $700 million private offering of 0.00% Convertible Senior Notes due 2031 to enhance its liquidity and financial flexibility. To mitigate dilution, the company entered into convertible note hedge transactions covering approximately 2.09 million shares and sold warrants with a $524.34 strike price, covering about 4.19 million shares, to help offset hedging costs. The notes are initially convertible at $334.27 per share and are senior unsecured.

Ligand (NASDAQ: LGND) sets $550M convert deal and $75M buyback

https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-021e83a52baa.html
Ligand Pharmaceuticals announced a private offering of $550 million in convertible senior notes due 2031, with an option for an additional $82.5 million. The company plans to use part of the proceeds for convertible note hedge and warrant transactions, repurchase up to $75 million of its common stock, and fund general corporate purposes, including the acquisition of Xoma Royalty Corporation. Concurrently, a Fourth Amendment to its Credit Agreement was made, adjusting minimum Consolidated EBITDA requirements to facilitate this offering.

Is It Too Late To Reassess Ligand Pharmaceuticals (LGND) After A 115% One-Year Rally?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-it-too-late-to-reassess-ligand-pharmaceuticals-lgnd-after
Ligand Pharmaceuticals (LGND) has seen a 115% rally over the last year, prompting a reassessment of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 34.3% with an intrinsic value of $377.63, while a P/E ratio comparison indicates it might be overvalued at 32.40x against its "Fair Ratio" of 20.62x. The article highlights that different valuation narratives can lead to varying conclusions on its true worth.

JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo

https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-9a3fe4b9d2c9.html
JALAA Equities LP reported the sale of 500 common shares of Ligand Pharmaceuticals (LGND) on June 10, 2026, for $124,980.42. The SEC filing also indicated 4,500 common shares associated with Wells Fargo Clearing Services, originally purchased on April 28, 2005. This Rule 144 notice details the disposition and linked shares, clarifying that the 500 shares sold by JALAA Equities LP were distinct from the Wells Fargo-linked shares.

Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan

https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-2152b67b1c2f.html
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, a non-binding advisory resolution on executive compensation, and an amendment and restatement of the Company’s 2002 Stock Incentive Plan. The approvals demonstrate strong investor support for the company's governance and compensation strategies.
Advertisement

Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants

https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-241ba3f79ea3.html
Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards comprising 836 restricted stock units (RSUs) and 2,938 non-qualified stock options with a strike price of $237.00 per share. These awards, granted on June 5, 2026, fully vest on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date. Following these compensation-related grants, Sabba directly holds 33,629 shares of Ligand common stock, in addition to the newly awarded options.

LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition

https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-72e3b6efebb9.html
Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. Additionally, 182 shares were withheld to cover tax liabilities associated with the RSU settlement, a non-market disposition.

Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants

https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-cc91da2f998a.html
Ligand Pharmaceuticals director Jason Haas received 836 restricted stock units (RSUs) and a non-qualified stock option for 2,938 shares as part of his board compensation on June 5, 2026. The RSUs and options fully vest on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date. Following these grants, Haas directly holds 7,442 shares of common stock, and the stock option has an exercise price of $237 per share and expires on June 5, 2036.

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-insider-sold-124838566.html
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit from a poor investment, as Reardon maintains significant direct and option holdings. The article highlights Ligand's strong one-year return and growing royalty revenue, advising investors to consider "The Motley Fool Stock Advisor" for top stock picks, though Ligand was not among them.

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

https://www.fool.com/coverage/filings/2026/06/07/a-ligand-pharmaceuticals-lgnd-insider-sold-5-000-shares-for-usd1-1-million/
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares for approximately $1.14 million on June 1, 2026, following the exercise of stock options. This sale, representing 10.78% of his direct holdings, capitalized on Ligand's strong 123.61% one-year total return. Post-transaction, Reardon still holds 41,382 direct shares and 39,444 employee stock options, indicating his interests remain aligned with investors.
Advertisement

Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

https://www.newsfilecorp.com/release/73129/Levi-Korsinsky-LLP-National-Class-Action-Law-Firm-Announces-Class-Action-Investigation-Against-Robinhood-and-Other-Brokers-on-Behalf-of-Investors-in-Ligand-Pharmaceuticals-Incorporated-NASDAQ-LGND?lang=fr
Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and also impacted other heavily shorted stocks, caused significant outrage among retail investors and led to calls for Congressional hearings. The law firm is seeking to represent investors who suffered losses due to these limitations imposed by brokerage firms.

LGND - Ligand Pharmaceuticals Inc Stock Price and Quote

https://finviz.com/stock?t=LGND
This page provides comprehensive financial data and news for Ligand Pharmaceuticals Inc. (LGND), including its stock price, key financial metrics, analyst ratings, and recent corporate announcements. It also details insider trading activities, offering a snapshot of the company's performance and significant events.

Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals
Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an uplift in its 2026 revenue and EPS outlook. Despite being considered undervalued by analysts, current valuation may already reflect much of the anticipated growth, with key risks including regulatory uncertainty and potential exclusivity loss on some royalty streams.

LGND: XOMA Buy Adds 100+ Assets

https://scr.zacks.com/news/news-details/2026/LGND-XOMA-Buy-Adds-100-Assets-article/default.aspx
Ligand Pharmaceuticals (NASDAQ: LGND) announced the acquisition of XOMA Royalty Corporation (NASDAQ: XOMA) for $739 million, adding over 100 assets to its portfolio. The all-cash transaction, expected to close in Q3 2026, is projected to be immediately accretive to Ligand's earnings, increasing 2026 revenue estimates by $25 million and EPS by $0.50. The acquisition also brings tax benefits and complements recent FDA approvals for Filspari and Tzield, reinforcing Ligand's strategy of building a diversified royalty portfolio.

Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company

https://www.tradingview.com/news/tradingview:19c64383e002f:0-ligand-pharmaceuticals-amends-xoma-royalty-merger-agreement-to-add-holding-company/
Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary of Ligand. The amendment aims to streamline the acquisition of XOMA Royalty.
Advertisement

Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company

https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-410835941783.html
Ligand Pharmaceuticals (LGND) has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation as a party, formalizing a Nevada holding company reorganization. This amendment clarifies the legal structure of the previously announced acquisition, with XOMA Royalty Holdings surviving as a wholly-owned subsidiary of Ligand. The transaction remains subject to regulatory approvals and XOMA Royalty stockholder approval.

Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

https://www.marketbeat.com/instant-alerts/filing-stephens-investment-management-group-llc-cuts-stock-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-05-17/
Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a "Moderate Buy" consensus rating, the company reported mixed quarterly results with EPS and revenue missing estimates. Insider selling by Stephen L. Sabba and Andrew Reardon also occurred within the last 90 days.

Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed

https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-d09558e82e6f.html
Ligand Pharmaceuticals reported strong Q1 2026 results with royalty revenue increasing 56% year-over-year to $43.0 million, primarily driven by products like Filspari, Ohtuvayre, and Capvaxive. Despite a GAAP net loss of $13.3 million due to non-cash items, adjusted net income rose 30% to $34.6 million. The company reaffirmed its full-year 2026 financial guidance, anticipating $225–$250 million in royalty revenue, and highlighted progress on the pending acquisition of XOMA Royalty.

UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND

https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-purchases-31081-shares-of-ligand-pharmaceuticals-incorporated-lgnd-2026-05-10/
UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms raising price targets and maintaining buy ratings despite the company missing Q1 EPS and revenue estimates, though revenue still grew year-over-year. Insider selling has also been noted, with the CFO and a director reducing their holdings.

A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination

https://finance.yahoo.com/markets/stocks/articles/look-ligand-pharmaceuticals-lgnd-valuation-111534266.html
Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months and is currently considered undervalued by analysts, trading at $220.48 against a narrative fair value of $246.70. The company's valuation is heavily influenced by its expanding high-margin royalty portfolio, although its P/E ratio of 28.8x is higher than the industry average, suggesting less room for error if expectations are not met.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement